SHIFT AI Newsroom · UK
Strengthened Warnings for GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists
The MHRA has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued strengthened warnings on acute pancreatitis, including necrotising and fatal cases, for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines.
What this means in the UK
This update is relevant to UK patients and healthcare professionals who use or prescribe these medicines, as it highlights the potential risk of acute pancreatitis, including necrotising and fatal cases.
Known facts
- The MHRA has issued strengthened warnings on acute pancreatitis for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists.